Pharmacokinetics of intravenous paracetamol in elderly patients

Clinical Pharmacokinetics

Volumn 50, Issue 2, 2011, Pages 121-129

  Liukas, Antti ^a   Kuusniemi, Kristiina ^a   Aantaa, Riku ^a   Virolainen, Petri ^a   Niemi, Mikko ^b   Neuvonen, Pertti J ^b   Olkkola, Klaus T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; BUPIVACAINE; CREATININE; FENTANYL; MORPHINE; NALOXONE; PARACETAMOL; PARACETAMOL GLUCURONIDE; PARACETAMOL SULFATE;

ADULT; AGE DETERMINATION; AGED; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; ORTHOPEDIC SURGERY; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETAMINOPHEN; ADULT; AGED; AGED, 80 AND OVER; AGING; ANALGESIA; ANALGESICS, NON-NARCOTIC; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 78751494687     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11537240-000000000-00000     Document Type: Article

References (29)

1. Hyllested M, Jones S, Pedersen JL, et al. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth 2002; 88: 199-214.
2. Elia N, Lysakowski C, Tramer MR. Does multimodal analgesia with aceta- minophen, nonsteroidal antiinflammatory drugs, orselective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Anesthesiology 2005; 103: 1296-304.
3. Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side- effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth 2005; 94: 505-13.
4. Sinatra RS, Jahr JS, Reynolds LW, et al. Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) of pain management after major orthopedic surgery. An-esthesiology 2005; 102: 822-31.
5. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharma- codynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998; 35: 49-64.
6. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008; 47: 297-321.
7. White M, Kenny GN, Schraag S. Use oftarget controlled infusionto derive age and gender covariates for propofol clearance. Clin Pharmacokinet 2008; 47: 119-27.
8. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67-76.
9. Miller RP, Roberts RJ, Fisher LJ. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 1976; 19: 284-94.
10. Hardwick LJ, Velamakanni S, van Veen HW. The emerging pharmaco- therapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol 2007; 151: 163-74.
11. Kondo C, Suzuki H, Itoda M, et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 2004; 21: 1895-903.
12. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
13. Vertzoni MV, Archontaki HA, Galanopoulou P. Development and optimi- zation of a reversed-phase high-performance liquid chromatographic method for the determination of acetaminophen and its major metabolites in rabbit plasma and urine after a toxic dose. J Pharmaceut Biomed 2003; 32: 487-93.
14. Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009; 86: 197-203.
15. Triggs EJ, Nation RL, Long A, et al. Pharmacokinetics in the elderly. Eur J Clin Pharmacol 1975; 8: 55-62.
16. Miners JO, Penhall R, Robinson RA, et al. Comparison of paracetamol me- tabolism in young adult and elderly males. Eur J Clin Pharmacol 1988; 35: 157-60.
17. Briant RH, Dorrington RE, Cleal J, et al. The rate of acetaminophen metab- olism in the elderly and the young. J Am Geriatr Soc 1976; 24: 359-61.
18. Divoll M, Abernethy DR, Ameer B, et al. Acetaminophen kinetics in the elderly. Clin Pharmacol Ther 1982; 31: 151-6.
19. Wynne HA, Cope LH, Herd B, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing 1990; 19: 419-24.
20. Zamek-Gliszczynski MJ, Nezasa K, Tian X, et al. The important role of bcrp (abcg2) in the biliary excretion of sulphate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 2006; 70: 2127-33.
21. Prescott LF, Speirs GC, Critchley JA, et al. Paracetamol disposition and me- tabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol 1989; 36: 291-7.
22. Bannwarth B, Pehourcq F, Lagrange F, et al. Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. J Rheumatol 2001; 28: 182-4.
23. Electronic Medicines Compendium UK. Perfalgan 10 mg/mL solution for infusion: summary of product characteristics [online]. Available from URL:l http://emc.medicines.org.uk/medicine/14288/SPC/Perfalgan%2010mg/ml% 20Solution%20for%20Infusion/ [Accessed 2010 Nov 8].
24. Sweetman S, editor. Martindale: the complete drug reference [electronic version]. London: Pharmaceutical Press, 2006 Sep 1.
25. Kaplowitz N. Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next? Hepatology 2004; 40: 23-6.
26. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296: 87-93.
27. Manyike PT, Kharasch ED, Kalhorn TF, et al. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther 2000; 67: 275-82.
28. Gelotte CK,Aulier JF,Lynch JM,etal.Dispositionofacetaminophenat4,6,and 8 g/day for 3 days in healthy young adults. Clin Pharmacol Ther 2007; 81: 840-8.
29. American Academy of Pediatrics Committee on Drugs. Acetaminophen toxi- city in children. Pediatrics 2001; 108: 1020-4